BETAMETHASONE (bay-ta-meth'a-sone) Betnelan , Celestone BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE Celestone Soluspan BETAMETHASONE BENZOATE Beben , Benisone, Uticort BETAMETHASONE DIPROPIONATE Alphatrex, Diprolene, Diprosone, Maxivate BETAMETHASONE SODIUM PHOSPHATE (PH 8.5) Betameth, Betnesol , Celestone Phosphate, Celestone S, Cel-U-Jec, Selestoject BETAMETHASONE VALERATE Betacort, Betaderm , Betatrex, Beta-Val, Betnovate , Celestoderm , Ectosone Lotion , Luxiq, Metaderm , Novobetamet , Valisone, Valisone Scalp Lotion, Valnac, Psorion cream Classifications: hormone and synthetic substitute; adrenal corticosteroid; glucocorticoid; antiinflammatory Prototype: Hydrocortisone Pregnancy Category: C |
Betamethasone 0.6 mg tablets; 0.6 mg/5 mL syrup
Betamethasone Acetate and Betamethasone Sodium 3 mg acetate, 3 mg sodium phosphate/mL suspension
Betamethasone Benzoate, Betamethasone Dipropionate, and Betamethasone Sodium Phosphate (pH 8.5) 4 mg/mL injection
Betamethasone Valerate 0.1% ointment; 0.01%, 0.05%, 0.1% cream; 0.1% lotion; 1.2 mg/g foam
Synthetic, long-acting glucocorticoid with minor mineralocorticoid properties but strong immunosuppressive, antiinflammatory, and metabolic actions.
Relieves antiinflammatory manifestations and is an immunosuppressive agent.
Reduces serum calcium in hypercalcemia, suppresses undesirable inflammatory or immune responses, produces temporary remission in nonadrenal disease, and blocks ACTH production in diagnostic tests. Topical use provides relief of inflammatory manifestations of corticosteroid-responsive dermatoses.
Prevention of neonatal respiratory distress syndrome (hyaline membrane disease).
In patients with systemic fungal infections. Pregnancy (category C), lactation, vaccines.
Ocular herpes simplex; concomitant use of aspirin; osteoporosis; diverticulitis, nonspecific ulcerative colitis, abscess or other pyrogenic infection, peptic ulcer disease; hypertension; renal insufficiency; myasthenia gravis.
Antiinflammatory Agent Adult: PO 0.67.2 mg/d IM/IV 0.59 mg/d as sodium phosphate Topical See Appendix A-4 Child: PO 0.01750.25 mg/kg/d or 0.50.75 mg/m2/d divided q68h Child: IM 0.01750.125 mg/kg/d or 0.50.75 mg/m2/d divided q68h Respiratory Distress Syndrome Adult: IM 2 mL of sodium phosphate to mother once daily 23 d before delivery |
Intravenous PREPARE: Direct: Give by direct IV undiluted or further diluted in D5W or NS. ADMINISTER: Direct: Give at a rate of 1 dose/min. INCOMPATIBILITIES Solution/additive: Amobarbital, ampicillin, bleomycin, colistimethate, dimenhydrinate, doxapram, doxorubicin, ephedrine, heparin, hydralazine, metaraminol, methicillin, nafcillin, pentobarbital, phenobarbital, prochlorperazine, promethazine, secobarbital, tetracycline. Y-site: Ergotamine, phenytoin. |
May increase serum cholesterol, blood glucose, serum sodium, uric acid (in acute leukemia) and calcium (in bone metastasis). It may decrease serum calcium, potassium, PBI, thyroxin (T4), triiodothyronine (T3) and reduce thyroid I 131 uptake. It increases urine glucose level and calcium excretion; decreases urine 17-OHCS and 17-KS levels. May produce false-negative results with nitroblue tetrazolium test for systemic bacterial infection and may suppress reactions to skin tests.
Assessment & Drug Effects
Patient & Family Education